Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation

Immunology

Volumn 138, Issue 3, 2013, Pages 258-268

  MacKenzie, Karen J ^a   Fitch, Paul M ^a,b   Leech, Melanie D ^a,b   Ilchmann, Anne ^a   Wilson, Claire ^c   McFarlane, Amanda J ^a   Howie, Sarah E M ^a   Anderton, Stephen M ^a,b   Schwarze, Jürgen ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NHS LOTHIAN   (United Kingdom)

Author keywords

Allergy; Asthma; Epitopes; Ovalbumin; Peptide immunotherapy

Indexed keywords

263 278 PEPTIDE; 323 339 PEPTIDE; ALLERGEN; EPITOPE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 5; OVALBUMIN; PEPTIDE DERIVATIVE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ALLERGIC AIRWAY INFLAMMATION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; EOSINOPHILIA; EPITOPE MAPPING; FEMALE; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG LAVAGE; MOUSE; NONHUMAN; PEPTIDE IMMUNOTHERAPY; PRIORITY JOURNAL; RISK REDUCTION; T LYMPHOCYTE;

ALLERGENS; AMINO ACID SEQUENCE; ANIMALS; ASTHMA; EOSINOPHILIA; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES;

EID: 84873308942     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12032     Document Type: Article

References (59)

1. Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol 2010; 11:577-84.
2. Anderson HR, Gupta R, Strachan DP, Limb ES. 50 years of asthma: UK trends from 1955 to 2004. Thorax 2007; 62:85-90.
3. Punekar YS, Sheikh A. Establishing the sequential progression of multiple allergic diagnoses in a UK birth cohort using the General Practice Research Database. Clin Exp Allergy 2009; 39:1889-95.
4. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008; 8:218-30.
5. Larché M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111:450-63.
6. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just Th2 cells. Nat Rev Immunol 2010; 10:838-48.
7. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009; 8:645-60.
8. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30-8.
9. Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010; 125:S306-13.
10. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev (Online) 2010:CD001186.
11. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev (Online) 2007:CD001936.
12. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-7.
13. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-8.
14. Caubet JC, Eigenmann PA. Late side-effects during systemic immunotherapy in children. Allergy 2008; 63:1561-2.
15. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11:S69-76.
16. Anderton SM. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology 2001; 104:367-76.
17. Larché M. Peptide immunotherapy for allergic diseases. Allergy 2007; 62:325-31.
18. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993; 5:1159-65.
19. Prakken BJ, van der Zee R, Anderton SM, van Kooten PJ, Kuis W, van Eden W. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci USA 1997; 94:3284-9.
20. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996; 93:956-60.
21. Anderton SM, Wraith DC. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur J Immunol 1998; 28:1251-61.
22. Burkhart C, Liu GY, Anderton SM, Metzler B, Wraith DC. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol 1999; 11:1625-34.
23. Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263:1139-43.
24. Alexander C, Tarzi M, Larche M, Kay AB. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005; 60:1269-74.
25. Oldfield WLG, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360:47-53.
26. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36:465-74.
27. Larché M. Of cats and men: immunodominance and the role of HLA-DP/DQ. Clin Exp Allergy 2008; 38:1709-11.
28. Kips JC, Anderson GP, Fredberg JJ et al. Murine models of asthma. Eur Respir J 2003; 22:374-82.
29. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76:34-40.
30. Shimonkevitz R, Colon S, Kappler JW, Marrack P, Grey HM. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol 1984; 133:2067-74.
31. Janssen EM, Wauben MH, Jonker EH, Hofman G, Van Eden W, Nijkamp FP, Van Oosterhout AJ. Opposite effects of immunotherapy with ovalbumin and the immunodominant T-cell epitope on airway eosinophilia and hyperresponsiveness in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1999; 21:21-9.
32. Barbey C, Donatelli-Dufour N, Batard P, Corradin G, Spertini F. Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance. Clin Exp Allergy 2004; 34:654-62.
33. + T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. Immunology 2010; 130:92-102.
34. Hochweller K, Anderton SM. Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo. Eur J Immunol 2005; 35:1086-96.
35. de Vries A, Hazlewood L, Fitch PM, Seckl JR, Foster P, Howie SE. High-fat feeding redirects cytokine responses and decreases allergic airway eosinophilia. Clin Exp Allergy 2009; 39:731-9.
36. + regulatory cells. J Immunol 2007; 179:7050-8.
37. Anderton SM, Manickasingham SP, Burkhart C, Luckcuck TA, Holland SJ, Lamont AG, Wraith DC. Fine specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J Immunol 1998; 161:3357-64.
38. Sweenie CH, Mackenzie KJ, Rone-Orugboh A, Liu M, Anderton SM. Distinct T cell recognition of naturally processed and cryptic epitopes within the immunodominant 35-55 region of myelin oligodendrocyte glycoprotein. J Neuroimmunol 2007; 183:7-16.
39. Hochweller K, Sweenie CH, Anderton SM. Circumventing tolerance at the T cell or the antigen-presenting cell surface: antibodies that ligate CD40 and OX40 have different effects. Eur J Immunol 2006; 36:389-96.
40. Maecker HT, Umetsu DT, DeKruyff RH, Levy S. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J Immunol 1998; 161:6532-6.
41. + T cell epitopes fused to heat shock cognate protein 70 (hsc70) can function to eradicate tumors. Cancer Sci 2008; 99:1008-15.
42. Gadola SD, Silk JD, Jeans A et al. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med 2006; 203:2293-303.
43. Janssen EM, van Oosterhout AJ, van Rensen AJ, van Eden W, Nijkamp FP, Wauben MH. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol 2000; 164:580-8.
44. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-87.
45. Lloyd CM, Hawrylowicz CM. Regulatory T cells in asthma. Immunity 2009; 31:438-49.
46. Campbell JD, Buckland KF, McMillan SJ et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009; 206:1535-47.
47. Gabrysova L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ, Wraith DC. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009; 206:1755-67.
48. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d 1. Proc Natl Acad Sci USA 1993; 90:7608-12.
49. Yang M, Mine Y. Novel T-cell epitopes of ovalbumin in BALB/c mouse: potential for peptide-immunotherapy. Biochem Biophys Res Commun 2009; 378:203-8.
50. Yang M, Yang C, Mine Y. Multiple T cell epitope peptides suppress allergic responses in an egg allergy mouse model by the elicitation of forkhead box transcription factor 3- and transforming growth factor-β-associated mechanisms. Clin Exp Allergy 2010; 40:668-78.
51. Mehlhop PD, van de Rijn M, Goldberg AB, Brewer JP, Kurup VP, Martin TR, Oettgen HC. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA 1997; 94:1344-9.
52. Korsgren M, Erjefalt JS, Korsgren O, Sundler F, Persson CG. Allergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient mice. J Exp Med 1997; 185:885-92.
53. Celik-Bilgili S, Mehl A, Verstege A, Staden U, Nocon M, Beyer K, Niggemann B. The predictive value of specific immunoglobulin E levels in serum for the outcome of oral food challenges. Clin Exp Allergy 2005; 35:268-73.
54. Holgate ST. A look at the pathogenesis of asthma: the need for a change in direction. Discov med 2010; 9:439-47.
55. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28-35.
56. Neill DR, Wong SH, Bellosi A et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367-70.
57. hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012; 188:1503-13.
58. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205:2887-98.
59. Moldaver D, Larche M. Immunotherapy with peptides. Allergy 2011; 66:784-91.